Advertisement

Search Results

Advertisement



Your search for all items matches 151 pages

Showing 151 - 151


hepatobiliary cancer

First-Line Brivanib Not Noninferior to Sorafenib in Advanced Hepatocellular Carcinoma

The investigational drug brivanib is a dual inhibitor of VEGF and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. In a noninferiority trial (BRISK-FL) reported in Journal of Clinical Oncology, Philip J. Johnson, MD, of the Institute of Translational Medicine,...

Advertisement

Advertisement



Advertisement